HEC Pharm Co., Ltd. is a pharmaceutical company that first entered the industry in 2001 through the acquisition of an API company in Yidu, Hubei. Since its humble beginnings with less than 100 employees and an annual turnover of not more than RMB 20 million, the company has experienced significant growth. By the end of 2009, HEC Pharm employed more than 3000 skilled personnel in three GMP certified pharmaceutical companies, which have been favorably inspected by US and European authorities, as well as one of the largest domestic Research Institutes. Notably, the corporation is the third company authorized by Roche to produce the anti-H1N1 drug Oseltamivir. Boasting six API synthesis plants with a fermentation capacity of more than 6000 tons, and five dosage form plants producing fifteen APIs and more than thirty drug products, HEC Pharm has established a strong presence with a marketing network that covers 30 provinces in China, Europe, and America. In 2009, the pharmaceutical product sales turnover reached USD 500 million.
The latest significant investment in HEC Pharm is a $400.00M post-IPO equity investment made on 15 August 2018 by the Blackstone Group. This investment highlights the confidence of a major player in the financial industry in the potential and growth prospects of HEC Pharm within the pharmaceutical sector. The substantial investment indicates a positive outlook for the company's future endeavors and development, positioning it as a noteworthy player in the pharmaceutical industry.
